Novo Nordisk Q1 sales jump 32%

Novo Nordisk just gave investors two very different stories in one quarter. The headline story was huge growth — sales up 32% at constant exchange rates, operating profit up 65%, and a guidance bump for the full year. But the underneath story was messier. Strip out a big one-off accounting benefit tied to the U.S. 340B drug-pricing program, and adjusted sales actually fell 4% while adjusted operating profit fell 6%. (attachment.news.eu.nasdaq.com) ### So what actually drove the big headline? The biggest driver was obesity drugs, especially the new Wegovy pill in the U.S. Novo launched it on January 5, 2026, and it ramped fast — DKK 2.256 billion in Q1 sales, around 1.3 million prescriptions in the quarter, and more than 2 million prescriptions since launch. We(attachment.news.eu.nasdaq.com)ume launch in the U.S. (attachment.news.eu.nasdaq.com) ### Why does the pill matter so much? Because pills widen the market. Injectable GLP-1 drugs like Wegovy and Ozempic already changed obesity and diabetes treatment, but a lot of patients and doctors still prefer tablets over shots. That makes an oral version more than just a line extension — it’s a way to pull in peo(attachment.news.eu.nasdaq.com)e same category, and whoever wins the pill market could shape the next leg of obesity-drug growth. (cnbc.com) ### What’s the catch in these numbers? The catch is that the reported surge was flattered by a one-time reversal of a U.S. 340B provision worth about USD 4.2 billion. That boosted reported sales and profit. On an adjusted basis, the quarter looked much less explosive. Novo’s own numbers show lower realized pr(cnbc.com)ing the medicines, but Novo is making less per prescription in some channels. (attachment.news.eu.nasdaq.com) ### Why are U.S. prices under pressure? Because the obesity-drug fight is getting more retail-like. Novo is leaning into broad access partnerships and high-volume distribution, which helps prescriptions grow but can squeeze pricing. U.S. adjusted sales fell 11% at constant exchange rates in the quarter, even with vol(attachment.news.eu.nasdaq.com)re. (attachment.news.eu.nasdaq.com) ### Did Novo raise guidance anyway? Yes — but only modestly. Novo now expects 2026 adjusted sales growth of -4% to -12% at constant exchange rates, versus its prior view of -5% to -13%. It also lifted adjusted operating profit guidance to the same -4% to -12% range. That still implies contraction for the year on an a(attachment.news.eu.nasdaq.com)egovy pill is doing well enough to make a difficult year look a bit less difficult. (attachment.news.eu.nasdaq.com) ### What else matters here? Novo said the first Wegovy pill launches outside the U.S. are expected in the second half of 2026, pending regulatory decisions. It also launched higher-dose injectable Wegovy HD in the U.S. on April 7 after FDA approval in March. So the company is trying to defend its obesity franchise on multiple fronts at once — pill, higher-dose shot, and broader access. (attachment.news.eu.nasdaq.com) ### Why did the market like this? Because expectations had gotten pretty low. The pill beat analyst forecasts by a wide margin, and the guidance lift signaled that Novo may be stabilizing after months of concern about competition and pricing. Shares jumped sharply in Copenhagen trading after the release. (attachment.news.eu.nasdaq.com)# Bottom line? Novo’s quarter was strong where investors most wanted proof — the Wegovy pill. But the company still has a pricing problem, and the clean numbers show that clearly. The bull case now is simple: if oral Wegovy keeps scaling and overseas launches land on time, Novo gets breathing room in a much tougher GLP-1 market. (attachment.news.eu.nasdaq.com)